^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

OPK 88004

i
Other names: OPK 88004, OPK-88004, LY2452473, TT 701, LY 2452473, OPK88004, Selective Androgen Receptor Modulator, TT701
Associations
Trials
Company:
Eli Lilly, OPKO Health
Drug class:
Selective androgen receptor modulator, Androgen receptor modulator
Associations
Trials
1m
Polypharmacological profiling across protein target families and cellular pathways using the multiplexed cell-based assay platform safetyProfiler reveals efficacy, potency and side effects of drugs. (PubMed, Biomed Pharmacother)
For example, the neuroleptics clozapine, paliperidone, and risperidone potently inhibited primary targets DRD2 and HTR2A as well as cAMP and calcium pathways...Additionally, precise potency data for LY2452473, an androgen receptor antagonist, that completed a phase 2 clinical trial for prostate cancer, are presented. The non-selective kinase inhibitor staurosporine was observed to potently inactivate the two RTKs EGFR and ERBB4 as well as MAPK signaling, while eliciting stress-related cAMP responses. Our findings underscore the value of comprehensive profiling in elucidating the pharmacological properties of established and novel therapeutics, thereby facilitating the development of novel multi-target drugs with enhanced efficacy and selectivity.
Journal • Adverse events
|
EGFR (Epidermal growth factor receptor) • ERBB4 (erb-b2 receptor tyrosine kinase 4) • DRD2 (Dopamine Receptor D2) • HTR2A (5-Hydroxytryptamine Receptor 2A)
|
OPK 88004
over2years
Effect of Selective Androgen Receptor Modulator on Cholesterol Efflux Capacity, Size, and Subspecies of HDL Particles. (PubMed, J Endocr Soc)
To determine the effects of an oral SARM (OPK-88004) on cholesterol efflux capacity, HDL particle number and size, apolipoprotein particle number and size and HDL subspecies...SARM-induced increase in HTGL could contribute to HDL-C suppression. These data do not support the simplistic notion that SARM-associated suppression of HDL-C is necessarily proatherogenic; randomized trials are needed to determine SARM's effects on cardiovascular events.
Journal
|
APOA1 (Apolipoprotein A-I) • APOB (Apolipoprotein B) • APOE (Apolipoprotein E)
|
OPK 88004